» Articles » PMID: 12424167

Oral Anticoagulation and Risk of Death: a Medical Record Linkage Study

Overview
Journal BMJ
Specialty General Medicine
Date 2002 Nov 9
PMID 12424167
Citations 42
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To study how mortality varies with different degrees of anticoagulation reflected by the international normalised ratio (INR).

Design: Record linkage analysis with death hazard estimated as a continuous function of INR.

Data Sources: 46 anticoagulation clinics in Sweden with computerised medical records.

Subjects: Records for 42 451 patients, 3533 deaths, and 1.25 million INR measurements.

Main Outcome Measures: Mortality from all causes and from intracranial haemorrhage.

Results: Mortality from all causes of death was strongly related to level of INR. Minimum risk of death was attained at 2.2 INR for all patients and 2.3 INR for patients with mechanical heart valve prostheses. A high INR was associated with an excess mortality: with an increase of 1 unit of INR above 2.5, the risks of death from cerebral bleeding (149 deaths) and from any cause were about doubled. Among patients with an INR of > or =3.0, 1069 deaths occurred within 7 weeks; if the risk coincided with that with an INR of 2.9, the expected number of deaths would have been 569. Thus at least 500 deaths were associated with a high INR value, but not necessarily caused by the treatment.

Conclusions: The excess mortality associated with high INR values supports the use of less intensive treatment and a small therapeutic window, with INR close to 2.2-2.3 irrespective of the indication for anticoagulant treatment. More preventive actions should be taken to avoid episodes of high INR.

Citing Articles

Potential Drug-Nutrient Interactions of 45 Vitamins, Minerals, Trace Elements, and Associated Dietary Compounds with Acetylsalicylic Acid and Warfarin-A Review of the Literature.

Renaud D, Holler A, Michel M Nutrients. 2024; 16(7).

PMID: 38612984 PMC: 11013948. DOI: 10.3390/nu16070950.


Diagnostic Performance of a Contrast-Enhanced Ultra-Low-Dose High-Pitch CT Protocol with Reduced Scan Range for Detection of Pulmonary Embolisms.

Brendlin A, Winkelmann M, Peisen F, Artzner C, Nikolaou K, Othman A Diagnostics (Basel). 2021; 11(7).

PMID: 34359338 PMC: 8304674. DOI: 10.3390/diagnostics11071251.


Stroke and Bleeding Risk Assessments in Patients With Atrial Fibrillation: Concepts and Controversies.

Ding W, Harrison S, Gupta D, Lip G, Lane D Front Med (Lausanne). 2020; 7:54.

PMID: 32154260 PMC: 7047213. DOI: 10.3389/fmed.2020.00054.


Letter to the Editor: A follow-up to 'The ability of triggers to predict potentially preventable adverse events in a sample of deceased patients'.

Klein D, Rennenberg R Prev Med Rep. 2019; 15:100920.

PMID: 31485389 PMC: 6715753. DOI: 10.1016/j.pmedr.2019.100920.


Characteristics of patients with thromboembolic disorders on warfarin therapy in resource limited settings.

Kamuren Z, Kigen G, Keter A, Maritim A BMC Health Serv Res. 2018; 18(1):723.

PMID: 30231891 PMC: 6145184. DOI: 10.1186/s12913-018-3537-4.


References
1.
Moinuddeen K, Quin J, Shaw R, Dewar M, Tellides G, Kopf G . Anticoagulation is unnecessary after biological aortic valve replacement. Circulation. 1998; 98(19 Suppl):II95-8; discussion II98-9. View

2.
Landefeld C, Beyth R . Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention. Am J Med. 1993; 95(3):315-28. DOI: 10.1016/0002-9343(93)90285-w. View

3.
Hirsh J . Optimal intensity and monitoring warfarin. Am J Cardiol. 1995; 75(6):39B-42B. DOI: 10.1016/0002-9149(95)80009-h. View

4.
Altman R, Rouvier J, Gurfinkel E, DOrtencio O, Manzanel R, de la Fuente L . Comparison of two levels of anticoagulant therapy in patients with substitute heart valves. J Thorac Cardiovasc Surg. 1991; 101(3):427-31. View

5.
Katircioglu S, Yamak B, Ulus A, Iscan H, Mavitas B, Tasdemir O . Aortic valve replacement with the St. Jude Medical prosthesis and fixed dose anticoagulation. J Card Surg. 1998; 12(6):363-70; discussion 371. DOI: 10.1111/j.1540-8191.1997.tb00152.x. View